Skip to main content
Home > The Daily Extra > Company News

Chronological Index of : Company News

 Current Issue
  • COMPANY NEWS: Perrigo's Papa to take helm at Valeant

    Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) named Joseph Papa chairman and CEO, effective in early May. He will replace longtime CEO Michael Pearson, who was also chairman until late February. Robert …

    Published on 4/25/2016
  • COMPANY NEWS: Unity, Ascentage in cellular senescence deal

    Anti-aging company Unity Biotechnology (San Francisco, Calif.) and Ascentage Pharma Group Corp. Ltd. (Hong Kong, China) partnered to develop small molecules to treat age-related diseases by selectively inducing death of…

    Published on 4/25/2016
  • COMPANY NEWS: Express Scripts eyes Ocrevus, dupilumab

    In comments to the American Journal of Managed Care, Express Scripts Holding Co. (NASDAQ:ESRX) Senior Clinical Consultant of Emerging Therapeutics Aimee Tharaldson said she is closely watching the progress of multiple …

    Published on 4/22/2016
  • COMPANY NEWS: Management tracks

    Oncology company FLX Bio Inc. (South San Francisco, Calif.) hired Rekha Hemrajani as COO. She was CFO and SVP of business and financial operations at 3-V Biosciences Inc. (Menlo Park, Calif.).Dermatology company Cipher …

    Published on 4/22/2016
  • COMPANY NEWS: Novartis splits departing exec Shaw's role in two

    Novartis AG (NYSE:NVS; SIX:NOVN) promoted two executives to replace Christi Shaw, who will leave the company. She was U.S. country head, president of Novartis Corp. and president of Novartis Pharmaceuticals Corp.…

    Published on 4/22/2016
  • COMPANY NEWS: AbbVie gets option for argenx mAb

    AbbVie Inc. (NYSE:ABBV) acquired an exclusive option from argenx N.V. (Euronext:ARGX) to license ARGX-115, a preclinical mAb against leucine-rich repeat containing 32 (LRRC32; GARP), to treat cancer. argenx will be …

    Published on 4/21/2016
  • COMPANY NEWS: Actelion reports first Uptravi sales, raises guidance

    Actelion Ltd. (SIX:ATLN) reported 1Q16 earnings, including the first sales of pulmonary arterial hypertension drug Uptravi selexipag, and raised its core operating income guidance to growth in the high single digits, …

    Published on 4/21/2016
  • COMPANY NEWS: AZ collecting 2 million genomes

    AstraZeneca plc (LSE:AZN; NYSE:AZN) will collaborate with Human Longevity Inc. (San Diego, Calif.), Genomics England Ltd. (London, U.K.) and several academic organizations to collect 2 million genomes over 10 years …

    Published on 4/21/2016
  • COMPANY NEWS: Biogen gains as cost-cutting drives earnings

    Biogen Inc. (NASDAQ:BIIB) added $13.71 to $279.60 on Thursday after it reported 1Q16 earnings that narrowly missed consensus revenue estimates, but topped non-GAAP EPS expectations as SG&A and R&D expenses decreased. …

    Published on 4/21/2016
  • COMPANY NEWS: NICE now backs Sanofi's Jevtana

    The U.K.'s NICE issued a final appraisal determination recommending Jevtana cabazitaxel from Sanofi (Euronext:SAN; NYSE:SNY) in combination with prednisone to treat metastatic hormone-relapsed prostate cancer in …

    Published on 4/21/2016
  • COMPANY NEWS: Novartis gives update on Entresto, Cosentyx launches

    Novartis AG (NYSE:NVS; SIX:NOVN) reported 1Q16 financial results on Thursday, including an update on the launch trajectory of heart failure drug Entresto sacubitril/valsartan. It said improved formulary access to …

    Published on 4/21/2016
  • COMPANY NEWS: Yabao, Salus partner in complex generics

    Yabao Pharmaceutical Group Co. Ltd. (Shanghai:600351) partnered with Salus Pharma LLC (Monmouth Junction, N.J.) to develop, manufacture and commercialize complex formulations of generics. Yabao will hold exclusive ex-U.…

    Published on 4/21/2016
  • COMPANY NEWS: Basilea lands BARDA contract for ceftobiprole

    Basilea Pharmaceutica AG (SIX:BSLN) said HHS's Biomedical Advanced Research and Development Authority awarded it a 4.5-year contract potentially worth $100 million to support Phase III trials of the company's …

    Published on 4/20/2016
  • COMPANY NEWS: GSK, Sanford Burnham Prebys form neuroscience center

    Sanford Burnham Prebys Medical Discovery Institute (La Jolla, Calif.) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) partnered to create the SBP-GSK Center for Translational Neuroscience. The center will aim to identify …

    Published on 4/20/2016
  • COMPANY NEWS: Hummingbird, Sanofi to develop cancer antibodies

    Hummingbird Bioscience Pte. Ltd. (Singapore) said it partnered with Sanofi (Euronext:SAN; NYSE:SNY) to develop therapeutic antibodies in oncology using Hummingbird's Rational Antibody Design technology. Hummingbird CEO …

    Published on 4/20/2016
  • COMPANY NEWS: Management tracks

    Oncology play Checkmate Pharmaceuticals Inc. (Cambridge, Mass.) hired David Mauro as CMO. He was EVP and CMO at Advaxis Inc. (NASDAQ:ADXS). Rare disease company Lumos Pharma Inc. (Austin, Texas) hired John McKew as CSO.…

    Published on 4/20/2016
  • COMPANY NEWS: FDA reviewing Synergy's plecanatide

    Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) said FDA accepted an NDA for plecanatide (SP-304) to treat chronic idiopathic constipation (CIC). The PDUFA date is Jan. 29, 2017. Last year, the guanylate cyclase C (GCC; …

    Published on 4/19/2016
  • COMPANY NEWS: Swiss Pharma files IPR challenge to Biogen's Tysabri

    Swiss Pharma International AG (Zurich, Switzerland) filed three inter partes review (IPR) petitions with the U.S. Patent and Trademark Office challenging patents from Biogen Inc. (NASDAQ:BIIB) covering multiple …

    Published on 4/19/2016
  • COMPANY NEWS: Chiasma sinks after FDA requests new Mycapssa trial

    Chiasma Inc. (NASDAQ:CHMA) plummeted $6.42 (63%) to $3.75 on Monday after it said FDA wants another trial of acromegaly candidate Mycapssa octreotide. The company disclosed Friday that it had received a complete …

    Published on 4/18/2016
  • COMPANY NEWS: FDA rejects Chiasma's Mycapssa

    Chiasma Inc. (NASDAQ:CHMA) said it received a complete response letter from FDA for acromegaly candidate Mycapssa octreotide. The company did not disclose FDA's rationale for the decision and did not respond to …

    Published on 4/15/2016
  • COMPANY NEWS: Management tracks

    Cancer company Gritstone Oncology Inc. (Emeryville, Calif.) hired Karin Jooss as CSO. She was head of cancer immunotherapeutics and immunopharmacology at Pfizer Inc. (NYSE:PFE). Microbiome company Vedanta Biosciences …

    Published on 4/15/2016
  • COMPANY NEWS: NICE backing PTC's Translarna

    The U.K.'s NICE recommended coverage of Translarna ataluren from PTC Therapeutics Inc. (NASDAQ:PTCT) under a managed access agreement with NHS England to treat nonsense mutation Duchenne muscular dystrophy (DMD) in …

    Published on 4/15/2016
  • COMPANY NEWS: CV/NASH play Madrigal finds public path via Synta merger

    Synta Pharmaceuticals Corp. (NASDAQ:SNTA) and Madrigal Pharmaceuticals Inc. (Fort Washington, Pa.) will reverse-merge to create a company focused on non-alcoholic steatohepatitis (NASH), cardiovascular and metabolic …

    Published on 4/14/2016
  • COMPANY NEWS: FDA panel to discuss Merck's bezlotoxumab

    FDA's Antimicrobial Drugs Advisory Committee will meet June 9 to discuss a BLA from Merck & Co. Inc. (NYSE:MRK) for bezlotoxumab (MK-6072) to prevent Clostridium difficile infection recurrence. The candidate is under …

    Published on 4/14/2016
  • COMPANY NEWS: FDA to review Opdivo for Hodgkin's lymphoma

    FDA accepted and granted Priority Review to an sBLA from Bristol-Myers Squibb Co. (NYSE:BMY) that would expand the label of Opdivo nivolumab to include treatment of classical Hodgkin's lymphoma (cHL) after prior …

    Published on 4/14/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993